Eidos Therapeutics News Releases http://ir.eidostx.com/ Eidos Therapeutics News Releases en Eidos Therapeutics to Present at the 2019 BMO Prescriptions for Success Healthcare Conference http://ir.eidostx.com/news-releases/news-release-details/eidos-therapeutics-present-2019-bmo-prescriptions-success SAN FRANCISCO , June 18, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX ) today announced that management will participate in a fireside chat at the 2019 BMO Prescriptions for Success Healthcare Conference on Tuesday, June 25 th at 2:40 p.m. EDT in New York, NY . Tue, 18 Jun 2019 08:00:00 -0400 Eidos Therapeutics News Releases 7106 Eidos Therapeutics Reports First Quarter 2019 Financial Results http://ir.eidostx.com/news-releases/news-release-details/eidos-therapeutics-reports-first-quarter-2019-financial-results SAN FRANCISCO , May 07, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX),  today reported its financial results for the first quarter ended March 31, 2019 and provided an update on the company’s recent achievements. “The initiation of our Phase 3 ATTRibute-CM study in the Tue, 07 May 2019 16:30:00 -0400 Eidos Therapeutics News Releases 7016 Eidos Therapeutics to Present at Two Upcoming Investor Conferences http://ir.eidostx.com/news-releases/news-release-details/eidos-therapeutics-present-two-upcoming-investor-conferences-1 SAN FRANCISCO , April 19, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX ) today announced that management will present at two upcoming investor conferences. Class of 2018 Biotech IPOs Investor Day The company will present on Friday, April 26 , 2019 at 3:30 p.m. ET. Fri, 19 Apr 2019 08:00:00 -0400 Eidos Therapeutics News Releases 6981 Eidos Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results http://ir.eidostx.com/news-releases/news-release-details/eidos-therapeutics-reports-fourth-quarter-and-year-end-2018 Phase 3 study of AG10 in patients with ATTR-CM (ATTRIBUTE-CM) underway SAN FRANCISCO , April 15, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the fourth quarter and full year ended December 31, 2018 and provided an update on the Mon, 15 Apr 2019 08:30:00 -0400 Eidos Therapeutics News Releases 6966 Eidos Therapeutics Announces Publication in the Journal of the American College of Cardiology (JACC) and Presentation at American College of Cardiology (ACC) Scientific Sessions http://ir.eidostx.com/news-releases/news-release-details/eidos-therapeutics-announces-publication-journal-american AG10 demonstrated equivalent, near-complete stabilization of TTR in wild-type and mutant subjects with TTR amyloid cardiomyopathy (ATTR-CM). AG10 treatment normalized serum TTR levels, a prognostic indicator of survival in ATTR-CM patients, in all mutant and wild-type subjects. Mon, 18 Mar 2019 09:30:00 -0400 Eidos Therapeutics News Releases 6916 Eidos Therapeutics to Present at 31st Annual ROTH Conference http://ir.eidostx.com/news-releases/news-release-details/eidos-therapeutics-present-31st-annual-roth-conference SAN FRANCISCO , March 11, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics , Inc. (Eidos) (Nasdaq: EIDX ) today announced that management is scheduled to participate in a fireside chat regarding Eidos at the 31 st Annual ROTH Conference on Monday, March 18 th at 8:30 a.m. PDT in Orange County, CA. Mon, 11 Mar 2019 04:00:00 -0400 Eidos Therapeutics News Releases 6901 Eidos Therapeutics Initiates ATTRibute-CM, a Phase 3 Study of AG10 in ATTR-CM with Registrational 12-month Endpoint http://ir.eidostx.com/news-releases/news-release-details/eidos-therapeutics-initiates-attribute-cm-phase-3-study-ag10 ATTRibute-CM study design, which incorporates feedback from the FDA , has the potential to accelerate registration with a 12-month primary endpoint of change in 6-minute walk distance (6MWD), followed by a 30-month endpoint of mortality and cardiovascular-related hospitalizations Trial sites Wed, 27 Feb 2019 07:00:00 -0500 Eidos Therapeutics News Releases 6896 Eidos Therapeutics to Host Conference Call and Webcast to Discuss ATTR-CM Phase 3 Trial (ATTRibute-CM) Design http://ir.eidostx.com/news-releases/news-release-details/eidos-therapeutics-host-conference-call-and-webcast-discuss-attr SAN FRANCISCO , Feb. 25, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need caused by transthyretin (TTR) amyloidosis (ATTR), today announced that it will host an investor webcast Mon, 25 Feb 2019 08:00:00 -0500 Eidos Therapeutics News Releases 6866 Eidos Therapeutics to Present at Two Upcoming Investor Conferences http://ir.eidostx.com/news-releases/news-release-details/eidos-therapeutics-present-two-upcoming-investor-conferences-0 SAN FRANCISCO , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX ) today announced that management will present at two upcoming investor conferences. SVB Leerink Global Healthcare Conference The company will present on Thursday, February 28 , 2019 at 11:00 a.m. ET. Thu, 21 Feb 2019 08:00:00 -0500 Eidos Therapeutics News Releases 6841 Eidos Therapeutics to Present at 37th Annual J.P. Morgan Healthcare Conference http://ir.eidostx.com/news-releases/news-release-details/eidos-therapeutics-present-37th-annual-jp-morgan-healthcare SAN FRANCISCO , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics , Inc. (Eidos) (Nasdaq: EIDX ) today announced that management will present a company overview at the 37 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9 th at 4:30 p.m. PST in San Francisco, CA. Wed, 02 Jan 2019 08:00:00 -0500 Eidos Therapeutics News Releases 6806